| Literature DB >> 30223846 |
Junhai Pan1, Xiaolong Ge1, Wei Zhou2, Xin Zhong1, Lihu Gu1, Hepan Zhu1, Xinlong Li1, Weilin Qi1, Xianfa Wang3.
Abstract
BACKGROUND: Postoperative complications, especially postoperative pancreatic fistulas, remain the major concern following pancreaticoduodenectomy (PD). Mesh-reinforced pancreatic anastomoses, including pancreatojejunostomy (PJ) and pancreatogastrostomy (PG), are a new effective technique in PD. This study was conducted to analyze the safety and efficacy of this new technique and to compare the results of mesh-reinforced PJ vs PG.Entities:
Keywords: Mesh; Pancreatic fistula; Pancreaticoduodenectomy; Pancreatogastrostomy; Pancreatojejunostomy
Mesh:
Year: 2018 PMID: 30223846 PMCID: PMC6142426 DOI: 10.1186/s12957-018-1491-6
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Baseline demographics in patients undergoing pancreatectomy
| Characteristic | All ( | PG group ( | PJ group ( | |
|---|---|---|---|---|
| Age* | 58.9 ± 1.0 | 60.9 ± 1.3 | 57.1 ± 1.5 | 0.07 |
| Men, | 65 (59.1) | 27 (52.9) | 38 (64.4) | 0.22 |
| BMI*, kg/m2 | 23.0 ± 0.3 | 22.6 ± 0.6 | 23.3 ± 0.4 | 0.28 |
| Comorbidities, | ||||
| Diabetes mellitus, | 22 (20) | 9 (17.6) | 13 (22.0) | 0.57 |
| Hypertension, | 27 (24.5) | 13 (25.5) | 14 (23.7) | 0.83 |
| Operation time*, min | 368.0 ± 8.2 | 342.4 ± 11.7 | 390.0 ± 10.8 | < 0.01 |
| ASA ≥ 3, | 19 (17.3) | 9 (17.6) | 10 (16.9) | 0.92 |
| Intraoperative blood transfusion, | 41 (37.3) | 14 (27.5) | 27 (45.8) | 0.048 |
| Estimated blood loss*, mL | 502.4 ± 48.3 | 392.2 ± 31.8 | 597.6 ± 84.2 | 0.03 |
| Pancreatic gland texture, | 0.55 | |||
| Soft, | 93 (84.5) | 42 (82.4) | 51 (86.4) | – |
| Hard, | 17 (15.5) | 9 (17.6) | 8 (13.6) | – |
| Mesh materials, | < 0.01 | |||
| Non-absorbable, | 59 (53.6) | 10 (19.6) | 49 (83.1) | – |
| Absorbable, | 51 (46.4) | 41 (80.4) | 10 (16.9) | – |
| Pancreatic duct size (> 4 mm), | 28 (25.5) | 14 (27.5) | 14 (23.7) | 0.66 |
| The time of anastomosis*, min | 27.4 ± 0.4 | 29.1 ± 0.7 | 27.9 ± 0.6 | 0.21 |
PG pancreatogastrostomy, PJ pancreatojejunostomy
*Value are expressed as the mean ± SE
Surgical indications in 110 pancreaticoduodenectomies
| All ( | PG group ( | PJ group ( | ||
|---|---|---|---|---|
| Ampullary carcinoma* | 35 (31.8) | 17 (33.3) | 18 (30.5) | 0.75 |
| Distal biliary cancer* | 16 (14.5) | 7 (13.7) | 9 (15.3) | 0.82 |
| Duodenal cancer* | 16 (14.5) | 7 (13.7) | 9 (15.3) | 0.82 |
| Ductal cancer* | 15 (13.6) | 7 (13.7) | 8 (13.6) | 0.98 |
| Cystic tumors* | 9 (8.2) | 4 (7.8) | 5 (8.5) | 0.90 |
| Endocrine tumors* | 5 (4.5) | 3 (5.9) | 2 (3.4) | 0.53 |
| Intraductal papillary mucinous tumor* | 5 (4.5) | 2 (3.9) | 3 (5.1) | 0.77 |
| Other indications* | 9 (8.2) | 4 (7.8) | 5 (8.5) | 0.90 |
PG pancreatogastrostomy, PJ pancreatojejunostomy
*Values are expressed as n (%)
Postoperative outcomes in 110 cases of pancreaticoduodenectomy
| Outcome | All ( | PG group ( | PJ group ( | |
|---|---|---|---|---|
| Postoperative complication, n (%) | 42 (38.2) | 18 (35.3) | 24 (40.7) | 0.562 |
| Mild complications, | 7 (6.4) | 3 (5.9) | 4 (6.8) | 0.848 |
| Major complications, | 35 (31.8) | 15 (29.4) | 20 (33.9) | 0.614 |
| CCI, mean ± SD | 32.7 ± 2.5 | 27.0 ± 2.1 | 37.0 ± 3.9 | 0.045 |
| Pancreatic fistula, | 11 (10.0) | 3 (5.9) | 8 (13.6) | 0.181 |
| Pancreatic fistula grade | 0.488 | |||
| A, | 3 (2.7) | 1 (2.0) | 2 (3.4) | – |
| B, | 6 (5.5) | 2 (3.9) | 4 (6.8) | – |
| C, | 2 (1.8) | 0 (0) | 2 (3.4) | – |
| Biliary fistula, | 9 (8.2) | 2 (3.9) | 7 (11.9) | 0.243 |
| Postoperative stay, mean ± SD | 23.2 ± 0.9 | 23.6 ± 1.6 | 22.8 ± 1.0 | 0.674 |
| Abdominal bleeding, | 8 (7.3) | 4 (7.8) | 4 (6.8) | 0.830 |
| Intra-abdominal fluid collection, | 14 (12.7) | 3 (5.9) | 11 (18.6) | 0.045 |
| Delayed gastric empting, | 11 (10.0) | 2 (3.9) | 9 (15.3) | 0.048 |
| Reoperations, | 3 (2.7) | 1 (2.0) | 2 (3.4) | 0.646 |
PG pancreatogastrostomy, PJ pancreatojejunostomy, CCI comprehensive complication index